Leveraging the spectral analysis methods from complex matrix interpolation, it is possible to identify conserved transcriptomic subspaces that correlate with distinct clinical phenotypes in Multiple Sclerosis across blood and cerebrospinal fluid.

This discovery has a Claude-generated validation package with a full experimental design.

Precise Hypothesis

Spine & Adversarial Read

• highThe core methodology term 'spectral analysis methods from complex matrix interpolation' is not defined precisely enough to distinguish it from decades-old standard techniques (SVD, CCA, MOFA+, mixOmics/DIABLO) already used extensively for multi-omics/multi-tissue integration; without a specific mathematical formalism showing what 'complex matrix interpolation' adds, this risks being a relabeling of existing methods with no methodological novelty.
  Not resolved in this EVP. Step 12 of METHODOLOGY explicitly flags this as requiring independent mathematical review before any novelty claim can be made; until the source hypothesis authors provide a precise formal definition distinguishing their method from standard CCA/SVD, this must be treated as an open gap, and the EVP should default to implementing standard CCA/SVD as the operational baseline.
• highNo paired or matched blood-CSF MS transcriptomic dataset is confirmed to exist in the required datasets list — the entire hypothesis is untestable as stated without this data, and the datasets actually available (GSE138614, GSE193770, GSE108000) are blood-only or single-tissue, making the 'across body compartments' claim currently unfalsifiable with existing pipeline assets.
  Acknowledged as the primary abort risk (Day 14 checkpoint). This is a genuine, unresolved gap: a dedicated data-discovery sprint (recommended 2 weeks, ~$8,000 analyst cost) must precede any compute spend, and COST_USD_MIN above assumes this sprint succeeds. If no such dataset exists publicly, the hypothesis requires new prospective sample collection, which would raise TIME_TO_RESULT_DAYS to 365+ and COST_USD_FULL by an order of magnitude — not currently budgeted.
• mediumGiven the documented single-cell limitation (DNMT1/ZNF740 signals are CD8+ T-cell-restricted and diluted in bulk tissue), any bulk CSF transcriptomic dataset — which will have even lower CD8+ T-cell representation than blood due to low CSF cellularity — is likely to show near-zero signal for these two targets regardless of whether the underlying biology is real, making a null result on the primary target-enrichment test ambiguous between 'hypothesis false' and 'wrong assay resolution.'
  Partially addressed via the deconvolution arm (Phase E, step 8) using CIBERSORTx with the existing scVI atlas as reference, but this is explicitly flagged in KNOWN_FAILURE_MODES as unreliable for CSF given low RNA yield and small CD8+ cell numbers in CSF specifically. A cell-sorted or single-cell CSF dataset would be required for a definitive test; this EVP proceeds with deconvolved bulk as a compromise but success/failure interpretation for DNMT1/ZNF740 specifically should be treated as lower-confidence than for CTSS/FGF2/SLCO2B1.

Experimental Protocol

ROI Projection

Implementation Sketch

# Phase A: Data assembly & QC
load blood_expr, csf_expr, clinical_meta from GEO/internal sources
assert paired_or_matched(blood_expr, csf_expr, clinical_meta)  # ABORT if false
normalize(blood_expr); normalize(csf_expr)
batch_correct(blood_expr, csf_expr, method='ComBat-seq')

# Phase B: Spectral subspace extraction
shared_genes = intersect(blood_expr.genes, csf_expr.genes)
X_blood = blood_expr[:, shared_genes]  # n_patients x n_genes
X_csf   = csf_expr[:, shared_genes]
C = cross_covariance(X_blood, X_csf)  # or joint block matrix
U, S, Vt = spectral_decompose(C, k=20)  # SVD / generalized eigendecomposition
scores_blood = X_blood @ U
scores_csf   = X_csf @ Vt.T

# Phase C: Phenotype correlation + enrichment
for k in range(20):
    r, p = spearman(scores_blood[:,k], clinical_phenotype)
    fdr_correct(p)
target_genes = ['DNMT1','ZNF740','CTSS','FGF2','SLCO2B1','TRIM28','SETDB1','EHMT2','BRD2','BRD3','BRD4']
enrichment_test(top_loadings(U, k=10), target_genes)  # hypergeometric

# Phase D: Conserved subspace test
principal_angles(U_blood_subspace, U_csf_subspace)

# Phase E: Deconvolution arm
celltype_fractions = CIBERSORTx(X_blood, reference=scVI_atlas)
X_blood_CD8 = deconvolve(X_blood, celltype_fractions, cell_type='CD8_T')
repeat(Phase B-D, on=X_blood_CD8)

# Phase F: Validation
train_test_split(patients, ratio=0.7)
repeat(Phase B-E, on=held_out_set)
compare_effect_sizes(discovery, replication)